Myosin Therapeutics Inc.

Advancing First-in-Class Therapies Into Clinical Development

health AI/biotech startup focused on oncology and neuroscience therapeutics

Visit website

StageSeed-backed and grant-funded

Raised$6M

Founded2020

Employees3

LocationJupiter, FL

Business modelB2B/B2C hybrid (clinical development collaborations and therapy development for oncology and neuroscience)

About

The mission of Myosin Therapeutics, Inc. is to improve health outcomes through the development of novel pharmacotherapies targeting members of the myosin family of molecular motors. Myosin Therapeutics is positioned as the first nanomotor platform company focused on oncology, with a proprietary nMotor system for drug discovery. nMotor is a full screening platform from HTS to validation and target selectivity profiling, enabling Myosin to develop a robust pipeline of oncology therapeutics. Myosin has used nMotor to develop a unique therapeutic to improve outcomes in Glioblastoma (GBM), a critical unmet need with a conservative estimated serviceable market of at least 10,000 cases yearly in the US alone. Additionally, Myosin is developing a unique neurotherapeutic to prevent relapse in METH use disorder, another critical unmet need. METH use disorder is a chronic disorder for which there are currently no FDA-approved medications. More broadly, preclinical studies indicate that first-in-class pharmacotherapeutics targeting NMII have value in many applications, including other substance use disorders, cancer, neural regeneration and infectious diseases. Further, approval of a clinically safe NMII inhibitor will enable scientific advancements into the study of NMII’s contribution to human physiology, such as learning and memory.

Product

Value proposition: First-in-class molecular motor therapies targeting cellular mechanics to treat cancer and neurological diseases, with a focus on directly targeting root causes rather than just symptom relief.
Regulatory: FDA Fast Track designation granted for MT-125 in glioblastoma

Founders

Courtney Miller — Co-founder and CEO
Patrick Griffin — Co-founder
Theodore Kamenecka — Co-founder

Products

MT-125 (oncology), MT-228 (oncology preclinical), MT-110 (neuro preclinical), MT-134 (musculoskeletal preclinical)

Key features

First-in-class therapies modulating molecular motor proteins (myosin) to affect tumor mechanics and neural plasticityTargeted therapies addressing root causes of disease beyond signaling cascadesPipeline across discovery to Phase 3 with preclinical candidatesClinical trial enrollment ongoing for MT-125 in glioblastoma

Technologies

Molecular motor therapytargeted oncology/neurology therapeuticsmolecular nanomotors (myosin)

Target conditions

Glioblastomacancerneuroplasticity disorders

Care settings

clinical development siteresearch labshospitals (clinical trials)

Certifications

FDA Fast Track Designation (for MT-125 in glioblastoma)

Awards

FDA Fast Track Designation for MT-125 in GlioblastomaNCI Bridge Grant for MT-125 glioblastoma

Traction metrics

Pipeline stages: Discovery to Phase 3MT-125 in glioblastoma clinical developmentPreclinical MT-228, MT-110, MT-134 programs

Investors

Mint12 PharmaUniversity of Florida VenturesDeepWork CapitalFlorida Opportunity FundNational Institutes of Health (NIH)Florida Department of HealthMayo Clinic VenturesDynagrow CapitalThe Sontag Innovation FundHHS

News

Myosin Therapeutics Closes Second Seed Round To Advance Clinical Trials for Innovative Cancer and Neuroscience Therapies – UF Innovate · 2025-03-03T17:34:53.000Z
Myosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed Glioblastoma · 2026-05-19T18:00:00.000Z
Myosin Therapeutics closes $3M seed round to advance its brain therapies, including for cancer - Refresh Miami · 2025-03-05T11:44:08.000Z
Myosin Therapeutics - Southeast Venture Showcase · 2025-01-15T00:00:00.000Z
Myosin Therapeutics Awarded Florida Cancer Innovation Fund Grant to Support STAR-GBM Clinical Trial · 2026-03-24T18:00:00.000Z
Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma · 2025-06-09T18:00:00.000Z

Browse similar startups

Related startups

Native Cardio, Inc. — Naples, FL
NAVCES — Miami, FL
nurturly peds — Boca Raton, FL
Okaloosa Cardiology — Crestview, FL
Oncoderm Labs — Miami, FL
oncologic.ai — Orlando, FL
Myri Health — Oklahoma City, OK
MyVitalz™, Inc. — Omaha, NE
Naima Health — Pittsburgh, PA
NanoCure AI — Frisco, TX
NanoKar Therapeutics — Salt Lake City, UT
Nash Patient Advocacy and Consulting LLC. — Rock Hill, SC

Profile updated Jul 29, 2026. Sources: myosintherapeutics.com